UCB's Cimzia touted as potential top-seller

Belgium's UCB is riding high today after it won the FDA nod for a new indication for Cimzia as a rheumatoid arthritis remedy. Company officials and some analysts said the drug could be an up-and-coming blockbuster. Report

Suggested Articles

fighting
Marketing

Keytruda's bladder cancer gene therapy rival wins in phase 3

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

by Angus Liu
Novartis headquarters
Pharma

FDA greenlights generics of Novartis' $3B MS star Gilenya

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

by Arlene Weintraub
armwrestle
Pharma

Gilead runs into pushback on HIV drug patent extension

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.

by Eric Sagonowsky